Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 13,266 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Adult Disease Clear all

Conditions: Advanced NSCLC
Interventions: REGN5093-M114, Cemiplimab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 11
States / cities: Orange, California • Denver, Colorado • Baltimore, Maryland + 7 more

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unusual Cancers of Childhood
Interventions: anti-thymocyte globulin, filgrastim, busulfan, carmustine, cyclophosphamide, cyclosporine, cytarabine, etoposide, fludarabine phosphate, melphalan, methotrexate, methylprednisolone, mycophenolate mofetil, tacrolimus, peripheral blood stem cell transplantation, umbilical cord blood transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: Up to 60 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Diabetes Mellitus, Aging
Interventions: Motivational support, PALS - Physical activity for lifetime success; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 50 Years and older
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Migraine
Interventions: CVT-427 (zolmitriptan inhalation powder); Drug
Lead sponsor: Acorda Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 3
States / cities: North Dartmouth, Massachusetts • Lincoln, Nebraska • Dallas, Texas

Conditions: Rheumatoid Arthritis
Interventions: Upadacitinib, Adalimumab, Upadacitinib Matching Placebo, Adalimumab Matching Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 487 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 85
States / cities: Flagstaff, Arizona • Glendale, Arizona • Peoria, Arizona + 75 more

Conditions: Liver Cancer
Interventions: doxorubicin hydrochloride, nolatrexed dihydrochloride; Drug
Lead sponsor: Eximias Pharmaceutical; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 38
States / cities: Tucson, Arizona • Little Rock, Arkansas • Beverly Hills, California + 31 more

Conditions: Lymphoma
Interventions: filgrastim, rituximab, sargramostim, carmustine, cyclophosphamide, etoposide, adjuvant therapy, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 70 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Lipoprotein Disorder
Interventions: LY3473329, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 40 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Baltimore, Maryland • Dorchester, Massachusetts • Lima, Ohio

Conditions: Colitis, Ulcerative
Interventions: Icotrokinra, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 12 Years and older
Enrollment: 896 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 56
States / cities: Chandler, Arizona • Litchfield Park, Arizona • Scottsdale, Arizona + 44 more

Conditions: Colitis Ulcerative
Interventions: SAR443122, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 14
States / cities: Lancaster, California • Atlanta, Georgia • Evanston, Illinois + 10 more

Conditions: Mantle Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Indolent Adult Non-Hodgkin Lymphoma
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cord Blood-derived Expanded Allogeneic Natural Killer Cells, Cytarabine, Etoposide, Filgrastim, Lenalidomide, Melphalan, Rituximab; Procedure · Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 15 Years to 70 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Yellow Fever, Immunization; Infection
Interventions: 17D; Biological
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 20 Years to 49 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Myelogenous Leukemia, Chronic
Interventions: nilotinib, imatinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 846 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2019
U.S. locations: 31
States / cities: Los Angeles, California • San Diego, California • Vallejo, California + 27 more

Conditions: Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm
Interventions: Bendamustine Hydrochloride, Quality-of-Life Assessment; Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 3
States / cities: Chicago, Illinois • Salt Lake City, Utah • Seattle, Washington

Conditions: CoronaVirus Induced Disease-2019 (COVID-19)
Interventions: Ibrutinib, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 9
States / cities: Stanford, California • Washington D.C., District of Columbia • Ft. Pierce, Florida + 4 more

Conditions: Anorexia Nervosa, Atypical Anorexia Nervosa
Interventions: Twenty Session Cognitive-Behavioral Therapy for Anorexia Nervosa (CBT-20-AN); Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cytomegalovirus (CMV), HIV (Human Immunodeficiency Virus)
Interventions: VIR-1388, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Birmingham, Alabama • Boston, Massachusetts

Conditions: Cardiovascular Diseases, Cardiac Rehabilitation, Transition of Care
Interventions: MACRO-I, Usual Care; Behavioral · Other
Lead sponsor: Daniel Forman, MD; Other
Eligibility: 70 Years and older
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 3
States / cities: St Louis, Missouri • Pittsburgh, Pennsylvania

Conditions: Pre Diabetes
Interventions: Finger Prick- Blood Glucose, Whole Blood Draw, Diet History Questionnaire, Physical Activity Assessment; Procedure · Behavioral
Lead sponsor: Cornell University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Ithaca, New York

Conditions: Relapsed or Refractory Multiple Myeloma
Interventions: Dexamethasone, Carfilzomib; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 31
States / cities: Palm Springs, California • Riverside, California • Glenwood Springs, Colorado + 26 more

Conditions: Multiple Sclerosis, Pain, Fatigue Symptom
Interventions: Self-guided smartphone application for relaxing acupressure, Self-guided smartphone application for stimulating acupressure; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Major Depressive Disorder
Interventions: OPC-34712, Placebo, ADT; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 773 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 43
States / cities: Birmingham, Alabama • Arcadia, California • Beverly Hills, California + 39 more

Conditions: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
Interventions: Investigational drug; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2002
U.S. locations: 12
States / cities: Berkeley, California • Greenbrae, California • Los Angeles, California + 9 more

Conditions: Major Depressive Disorder
Interventions: MBCT Intervention; Behavioral
Lead sponsor: Clemson University; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Clemson, South Carolina • Greenville, South Carolina

Search by objective public record fields.

Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

MY PALS: A Community-Based Physical Activity Support Program for Older Adults

A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder

Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

Nolatrexed Dihydrochloride Compared With Doxorubicin in Treating Patients With Recurrent or Unresectable Liver Cancer

Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell Lymphoma

A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis

Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma

Immunogenicity of Yellow Fever Vaccine 17D in Adults With Prior 17D Vaccination

A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma

Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury

Evaluation of a Twenty-session Cognitive-behavioral Therapy With Anorexia Nervosa (CBT-20-AN) Among Adults (18+)

A Clinical Study to Evaluate the Safety and Immunogenicity of a Higher Dose of the Study Vaccine, VIR-1388, in HCMV-seropositive Adult Participants Without HIV

Modified Application of Cardiac Rehabilitation for Older Adults

The Effect of Nutrient Sequencing in Healthy Adults

A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers

Usability of the MeTime MS App

Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder

Study of the Efficacy of an Investigational Drug in Adult Patients With Non Small-Cell Lung Cancer (NSCLC)

Virtual Mindfulness Training for Adults With History of Depression